Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript

Impact · against what's priced in

The provided transcript contains only introductory remarks and logistical information from Amgen's ESMO conference call. It lacks the actual data or clinical results necessary to impact the current valuation of the company's pipeline or revenue assumptions.

AMGN+0.00: Doesn't touch the price's assumptions
In context: The article is a transcript of the introductory remarks for an investor call; it does not present the clinical data or updates on MariTide or legacy products required to shift the current price.

Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript

How each ticker is affected

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript

How each ticker is affected

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Track these names every morning.

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence

Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript

How each ticker is affected

Next reads from the same story arc

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Amgen Inc. (AMGN) Presents at 2026 European Society for Medical Oncology (ESMO) Annual Congress Transcript

How each ticker is affected

Next reads from the same story arc

Amgen vs. Johnson & Johnson: Which Healthcare Giant Has the Better Stock to Buy?

Track these names every morning.

Amgen says drug combo cuts risk of death by 58% in patients with aggressive lung cancer

IMDELLTRA® IN COMBINATION WITH IMFINZI® REDUCED RISK OF DEATH BY AN UNPRECEDENTED 58% IN FIRST-LINE EXTENSIVE STAGE SMALL CELL LUNG CANCER

BeOne Presents Compelling Data in Hard-to-Treat Liver and Lung Cancers at ESMO 2026

Darolutamide plus ADT and radiation therapy reduces risk of metastasis or death by 58% in prostate cancer patients at high risk of recurrence